A Multicenter, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of Evolocumab
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Sep 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease; Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Amgen
- 16 Jun 2017 Planned End Date changed from 1 Jul 2018 to 31 Aug 2018.
- 16 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 31 Aug 2018.
- 19 Aug 2016 Status changed from recruiting to active, no longer recruiting.